deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in alzheimers disease缺乏肝二十二碳六烯酸的生物合成与认知障碍的阿尔茨海默氏症.pdfVIP

Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer’s Disease 1,2 1 3 4 4 Giuseppe Astarita , Kwang-Mook Jung , Nicole C. Berchtold , Vinh Q. Nguyen , Daniel L. Gillen , 5 3 1,6,7 Elizabeth Head , Carl W. Cotman , Daniele Piomelli * 1 Department of Pharmacology, University of California Irvine, Irvine, California, United States of America, 2 Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy, 3 Institute for Brain Aging and Dementia, University of California Irvine, Irvine, California, United States of America, 4 Department of Statistics, University of California Irvine, Irvine, California, United States of America, 5 Sanders-Brown Center on Aging, University of Kentucky, Lexington, Kentucky, United States of America, 6 Department of Biological Chemistry, University of California Irvine, Irvine, California, United States of America, 7 Unit of Drug Discovery and Development, Italian Institute of Technology, Genoa, Italy Abstract Reduced brain levels of docosahexaenoic acid (C22:6n-3), a neurotrophic and neuroprotective fatty acid, may contribute to cognitive decline in Alzheimer’s disease. Here, we investigated whether the liver enzyme system that provides docosahexaenoic acid to the brain is dysfunctional in this disease. Docosahexaenoic acid levels were reduced in temporal cortex, mid-frontal cortex and cerebellum of subjects with Alzheimer’s disease, compared to control subjects (P = 0.007). Mini Mental State Examination (MMSE) scores positively co